Specifications TableSubjectToxicologySpecific subject areaToxicity profiling of Sepin-1 in Sprague-Dawley RatsType of dataTablesHow data were acquiredBody and organ weights were collected by using a standard measuring scale. Hematology data were obtained using Siemens Advia 120 Hematology System (Siemens Healthineers, Erlangen, Germany). Clinical chemistry data were collected using Randox Imola Clinical Chemistry Analyzer (Randox Laboratories-US, Ltd, Kearneysville, WV).Data formatRaw, AnalysedExperimental factorsBody and organ weights were collected. Hematology and clinical chemistry parameters were obtained from blood samples.Experimental FeaturesBody and organ were weighed. Blood samples collected with K~2~EDTA were analyzed for the hematology parameters using Siemens Advia 120 Hematology System. Clotted blood samples were centrifuged, and the serum was used for the clinical chemistry analyses using Randox Imola Clinical Chemistry Analyzer.Data source locationBaylor College of Medicine\
Houston, Texas 77030\
USAData accessibilityWith the article**Value of the Data**•Sepin-1 is a novel inhibitor of Separase and its toxicity is unknown in animals. These data are collected in a GLP setting and useful for Sepin-1 to be further developed in pre-clinical and clinical studies.•Researchers in cancer research, pharmacology, toxicology and pharmaceutics will benefit from these data.•These data can be used to further study Sepin-1 in haematopoiesis, mechanisms of toxicity, and metabolism.

1. Data {#sec1}
=======

The dataset in this article contains body and organ weights, hematology, and clinical chemistry parameters in Sprague-Dawley rats that were dosed with Separase inhibitor--Sepin-1 in Good Laboratory Practice (GLP) setting. The animals randomly assigned in two study groups--Main Study and Recovery Study. Both study groups were dosed with Sepin-1 once daily for 28 consecutive days. Animals in Main Study group were terminated on day 29. Animals in Recovery Study were allowed to recover for 28 days and terminated on day 57. On the termination day organ weights were collected and blood samples were obtained for hematology and clinical chemistry analyses. [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} show group mean body weights data in Main Study and Recovery Study, respectively, which were collected twice a week. [Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"} are group mean organ weights, organ weights relative to brain weight, and organ weights relative to body weight in rats of Main Study, respectively. [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}, [Table 8](#tbl8){ref-type="table"} describe group mean organ weights, organ weights relative to brain weight, and organ weights relative to body weight in rats of Recovery Study, respectively. [Table 9](#tbl9){ref-type="table"}, [Table 10](#tbl10){ref-type="table"} show group mean hematology parameters in male and female rats of Main Study, respectively. [Table 11](#tbl11){ref-type="table"}, [Table 12](#tbl12){ref-type="table"} display group mean hematology parameters in male and female rats of Recovery Study, respectively. [Table 13](#tbl13){ref-type="table"}, [Table 14](#tbl14){ref-type="table"} show group mean clinical chemistry parameters in male and female rats of Main Study, respectively. [Table 15](#tbl15){ref-type="table"}, [Table 16](#tbl16){ref-type="table"} show group mean clinical chemistry parameters in male and female rats of Recovery Study, respectively. These data are complementary to the toxicity study of Sepin-1 in Sprague-Dowley rats published previously \[[@bib1]\].Table 1Group mean body weights (g) of rats in Main Study.Table 1Group 1 (0 mg/kg)Group 2 (5 mg/kg)Group 3 (10 mg/kg)Group 4 (20 mg/kg)Mean ± SDNMean ± SDNMean ± SDNMean ± SDNBody weight (g) of male rats in Main StudyPredose256.71 ± 9.0510256.36 ± 10.139258.88 ± 12.1910259.35 ± 11.478Day 1265.73 ± 12.6510264.14 ± 12.429274.45 ± 11.5410274.64 ± 11.038Day 4280.32 ± 11.810268.73 ± 15.239280.12 ± 8.6510277.21 ± 11.248Day 9303.22 ± 14.6310293.07 ± 10.849297.00 ± 10.3310292.07 ± 13.138Day 11311.12 ± 16.6710302.96 ± 12.99304.31 ± 12.810293.7 ± 21.98Day 15325.66 ± 19.0410318.34 ± 13.539315.55 ± 14.8810306.44[a](#tbl1fna){ref-type="table-fn"}±17.588Day 18333.95 ± 17.3710324.56 ± 12.519318.41 ± 13.8210311.03[a](#tbl1fna){ref-type="table-fn"}±20.858Day 22347.71 ± 22.179339.88 ± 14.219330.40 ± 19.410326.2 ± 16.627Day 25353.8 ± 25.499346.72 ± 12.859339.50 ± 14.3410327.64[a](#tbl1fna){ref-type="table-fn"}±15.917Day 28364.99 ± 24.929353.14 ± 14.398348.46 ± 14.7410344.47 ± 20.117Body weight (g) of female rats in Main StudyPredose206.04 ± 9.0910207.15 ± 8.199208.71 ± 8.028208.98 ± 8.058Day 1207.47 ± 10.1510204.79 ± 14.999214.34 ± 7.498213.5 ± 7.178Day 4219.16 ± 7.7710211.37 ± 6.019220.09 ± 8.898215.41 ± 6.78Day 9229.33 ± 8.6110224.73 ± 7.079227.94 ± 9.928225.78 ± 6.678Day 11230.97 ± 12.1910228.97 ± 7.239232.73 ± 10.368230.24 ± 10.188Day 15241.01 ± 11.3310239.78 ± 7.99242.99 ± 12.898236.67 ± 10.998Day 18243.97 ± 8.9910239.29 ± 8.229244.17 ± 9.068242.05 ± 15.828Day 22249.09 ± 12.710252.86 ± 10.529250.57 ± 68247.31 ± 8.578Day 25253.32 ± 16.3510248.6 ± 10.639248.81 ± 11.78243.42 ± 12.078Day 28260.57 ± 19.6510254.24 ± 11.369253.74 ± 13.098250.47 ± 10.478[^1]Table 2Group mean body weights (g) of rats in Recovery Study.Table 2Group 1 (0 mg/kg)Group 2 (5 mg/kg)Group 3 (10 mg/kg)Group 4 (20 mg/kg)Mean ± SDNMean ± SDNMean ± SDNMean ± SDNBody weight (g) of male rats in Recovery StudyPredose252.54 ± 30.15240.82 ± 24.665234.74 ± 21.465249.77 ± 22.345Day 1275.01 ± 32.235261.21 ± 18.855275.35 ± 20.645271.32 ± 20.475Day 4278.26 ± 28.855262.18 ± 28.485262.12 ± 16.665274.55 ± 17.975Day 8296.74 ± 26.315285.56 ± 28.375275.35 ± 20.645292.16 ± 18.095Day 11309.2 ± 28.075294.65 ± 38.35288.58 ± 22.115301.75 ± 18.395Day 16327.72 ± 26.075318.74 ± 27.355300.36 ± 25.965312.27 ± 18.275Day 18332.39 ± 25.375325.79 ± 30.45305.13 ± 31.925317.44 ± 17.425Day 22351.14 ± 255338.12 ± 33.885318.17 ± 31.835331.59 ± 17.065Day 25356.89 ± 22.65345.8 ± 34.325323.93 ± 28.485337.24 ± 15.445Day 29372.95 ± 25.035360.19 ± 34.885335.05 ± 31.325350.0614.525Day 32380.17 ± 25.25367.23 ± 34.875336.18 ± 33.555350.97 ± 11.55Day 36393.44 ± 24.225380.25 ± 34.145351.32 ± 31.65371.86 ± 7.15Day 39397.91 ± 25.195372.15 ± 28.524356.67 ± 32.025364.64 ± 17.553Day 43406.92 ± 24.845394.28 ± 38.185370.74 ± 29.115370.72 ± 39.125Day 50424.56 ± 24.115412.35 ± 37.795386.79 ± 27.285398.55 ± 15.645Day 53424.44 ± 28.454405.23 ± 33.134391.6 ± 26.765404.7 ± 14.673Day 56431.85 ± 29.764426.76 ± 36.625402.34 ± 27.965416.53 ± 12.235Body weight (g) of female rats in Recovery StudyPredose209.63 ± 19.785211.49 ± 18.335208.96 ± 15.035208.26 ± 13.035Day 1221.69 ± 29.325221.32 ± 15.365217.71 ± 12.765218.35 ± 11.865Day 4222.38 ± 26.435226.56 ± 12.065222.16 ± 11.295219.14 ± 12.715Day 8234.04 ± 22.055237.02 ± 10.885230.3 ± 9.025229.06 ± 12.575Day 11243.3 ± 18.745238.84 ± 10.765236.28 ± 11.345235.91 ± 11.795Day 16246.66 ± 19.345247.71 ± 13.155243.11 ± 10.225244.36 ± 15.145Day 18244.33 ± 25.275248.8 ± 13.715247.91 ± 9.885245.04 ± 13.335Day 22263.52 ± 16.865257.63 ± 12.165257.6 ± 12.75252.69 ± 15.075Day 25265.83 ± 16.665261.37 ± 14.15251.78 ± 8.315253.14 ± 13.465Day 29270.11 ± 19.795269.31 ± 15.855259.36 ± 7.985264.45 ± 16.725Day 32270.06 ± 18.515267.37 ± 17.985258.48 ± 7.665262.77 ± 15.695Day 36277.11 ± 15.65264.72 ± 24.875258.39 ± 8.755265.21 ± 15.555Day 39278.55 ± 15.165272.68 ± 21.483259.94 ± 9.883273.91 ± 16.313Day 43272.53 ± 20.545281.46 ± 22.074262.54 ± 8.735272.18 ± 19.665Day 50285.32 ± 20.395287.65 ± 23.944271.1 ± 11.235278.29 ± 18.995Day 53285.16 ± 17.35279.8 ± 21.53268.97 ± 11.943288.93 ± 18.673Day 56292.3 ± 14.865291.36 ± 18.184275.58 ± 11.475289.22 ± 25.345[^2]Table 3Group mean organ weights (g) of rats in Main Study (Day 29).Table 3Organ weight (g) of male rats in Main StudyGroup (Dose)NBrainKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)101.858±\
0.1002.429±\
0.1840.0675±\
0.01873.537±\
0.3780.629±\
0.0851.188±\
0.1612.086±\
0.2630.487±\
0.10310.829±\
1.4410.856±\
0.1542 (5 mg/kg)91.957[a](#tbl3fna){ref-type="table-fn"}±\
0.1082.658±\
0.2390.0747±\
0.01673.902[a](#tbl3fna){ref-type="table-fn"}±\
0.2980.547±\
0.1101.205±\
0.1582.164±\
0.3760.455±\
0.06911.215±\
0.7930.898±\
0.1473 (10 mg/kg)101.852±\
0.0452.597±\
0.2410.0673±\
0.01133.680±\
0.2110.585±\
0.1131.187±\
0.1992.443±\
0.7790.357[a](#tbl3fna){ref-type="table-fn"}±\
0.06110.964±\
0.7941.058±\
0.1914 (20 mg/kg)81.903±\
0.0712.760[a](#tbl3fna){ref-type="table-fn"}±\
0.2590.1431±\
0.21573.747±\
0.0980.522±\
0.1961.413[a](#tbl3fna){ref-type="table-fn"}±\
0.1872.557±\
0.4180.364[a](#tbl3fna){ref-type="table-fn"}±\
0.11911.353±\
1.5071.695[a](#tbl3fna){ref-type="table-fn"}±\
0.361Organ weight (g) of female rats in Main StudyGroup (Dose)NBrainKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)101.841±\
0.0741.710±\
0.1560.0889±\
0.02170.170±\
0.0290.922±\
0.1251.924±\
0.2190.339±\
0.0667.745±\
0.9270.722±\
0.1852 (5 mg/kg)91.760±\
0.1081.697±\
0.1560.0839±\
0.01490.170±\
0.0460.911±\
0.0581.864±\
0.2350.315±\
0.0837.967±\
0.8020.690±\
0.3073 (10 mg/kg)81.775±\
0.0971.713±\
0.1240.0810±\
0.00800.195±\
0.0230.962±\
0.0932.197±\
0.5360.279±\
0.0498.107±\
0.6990.836±\
0.1194 (20 mg/kg)81.816±\
0.0871.824±\
0.1960.0865±\
0.01080.177±\
0.0241.080[a](#tbl3fna){ref-type="table-fn"}±\
0.1321.975±\
0.3160.262[a](#tbl3fna){ref-type="table-fn"}±\
0.0388.639±\
0.5141.214[a](#tbl3fna){ref-type="table-fn"}±\
0.289[^3]Table 4Group mean organ weights relative to brain weight (%) of rats in Main Study (Day 29).Table 4Relative organ to brain weight (%) of males in Main StudyGroup (Dose)NKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)10131.02±\
12.193.67±\
1.16190.77±\
22.2834.06±\
6.0364.01±\
8.76112.57±\
15.6126.26±\
5.54584.66±\
87.0746.11±\
8.202 (5 mg/kg)9135.98±\
11.483.82±\
0.87199.85±\
17.9927.74±\
4.5661.65±\
7.95110.38±\
15.5423.22±\
3.27573.94±\
41.7345.67±\
5.003 (10 mg/kg)10140.20±\
11.363.64±\
0.61198.85±\
12.3831.72±\
6.1264.06±\
10.10131.74±\
41.0019.30±\
3.29592.49±\
45.2357.12±\
10.024 (20 mg/kg)8145.26±\
15.397.33±\
10.70197.11±\
8.7129.83±\
12.0374.52±\
11.55134.67±\
23.7719.21±\
6.65597.66±\
86.5488.92[a](#tbl4fna){ref-type="table-fn"}±\
17.33Relative organ to brain weight (%) of females in Main StudyGroup (Dose)NKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)1092.91±\
8.384.83±\
1.169.22±\
1.5450.09±\
6.56104.68±\
13.0218.37±\
3.35420.54±\
46.5739.34±\
10.302 (5 mg/kg)996.40±\
5.464.79±\
0.969.65±\
2.5751.81±\
2.53105.97±\
12.5917.88±\
4.72453.17±\
41.7439.29±\
17.323 (10 mg/kg)896.62±\
7.064.60±\
0.6710.98±\
1.0554.18±\
3.73123.31±\
26.5815.78±\
3.05457.75±\
43.9646.96±\
4.484 (20 mg/kg)8100.26±\
7.964.78±\
0.709.83±\
1.7459.40[a](#tbl4fna){ref-type="table-fn"}±\
6.03109.12±\
19.0014.40±\
1.86475.85[a](#tbl4fna){ref-type="table-fn"}±\
21.0166.80[a](#tbl4fna){ref-type="table-fn"}±\
15.37[^4]Table 5Group mean organ weights relative to body weight (%) of rats in Main Study (Day 29).Table 5Relative organ to body weight (%) of male rats in Main StudyGroup (Dose)NBrainKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)100.51±\
0.040.67±\
0.020.02±\
0.000.98±\
0.090.17±\
0.030.33±\
0.030.58±\
0.050.13±\
0.022.98±\
0.250.24±\
0.052 (5 mg/kg)90.55[a](#tbl5fna){ref-type="table-fn"}±\
0.020.75[a](#tbl5fna){ref-type="table-fn"}±\
0.060.02±\
0.001.10[a](#tbl5fna){ref-type="table-fn"}±\
0.070.18±\
0.100.34±\
0.040.61±\
0.100.13±\
0.023.16±\
0.190.25±\
0.043 (10 mg/kg)100.53±\
0.020.75[a](#tbl5fna){ref-type="table-fn"}±\
0.060.02±\
0.001.06±\
0.080.19±\
0.090.34±\
0.060.70±\
0.200.10[a](#tbl5fna){ref-type="table-fn"}±\
0.023.15±\
0.260.30[a](#tbl5fna){ref-type="table-fn"}±\
0.054 (20 mg/kg)80.55[a](#tbl5fna){ref-type="table-fn"}±\
0.030.80[a](#tbl5fna){ref-type="table-fn"}±\
0.070.04±\
0.061.09[a](#tbl5fna){ref-type="table-fn"}±\
0.050.16±\
0.060.41[a](#tbl5fna){ref-type="table-fn"}±\
0.070.74[a](#tbl5fna){ref-type="table-fn"}±\
0.130.11[a](#tbl5fna){ref-type="table-fn"}±\
0.033.29±\
0.370.49[a](#tbl5fna){ref-type="table-fn"}±\
0.09Relative organ to body weight (%) of female rats in Main StudyGroup (Dose)NBrainKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)100.71±\
0.050.66±\
0.050.03±\
0.010.07±\
0.010.35±\
0.040.74±\
0.070.13±\
0.022.97±\
0.210.28±\
0.062 (5 mg/kg)80.69±\
0.030.67±\
0.040.03±\
0.010.07±\
0.020.36±\
0.020.73±\
0.080.12±\
0.033.13±\
0.250.30±\
0.083 (10 mg/kg)80.70±\
0.050.68±\
0.040.03±\
0.000.08±\
0.010.38±\
0.030.86±\
0.200.11±\
0.023.19±\
0.210.33±\
0.054 (20 mg/kg)80.73±\
0.030.73[a](#tbl5fna){ref-type="table-fn"}±\
0.070.03±\
0.000.07±\
0.010.43[a](#tbl5fna){ref-type="table-fn"}±\
0.050.79±\
0.130.10±\
0.013.45[a](#tbl5fna){ref-type="table-fn"}±\
0.200.48[a](#tbl5fna){ref-type="table-fn"}±\
0.11[^5]Table 6Group mean organ weights (g) of rats in Recovery Study (Day 57).Table 6Organ weight (g) of male rats in Recovery StudyGroup (Dose)NBrainKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)52.029±\
0.1192.741±\
0.3180.0684±\
0.01163.891±\
0.3660.800±\
0.1381.456±\
0.1672.781±\
0.7210.379±\
0.05711.551±\
1.3890.887±\
0.1352 (5 mg/kg)51.936±\
0.0872.909±\
0.3090.0700±\
0.03303.692±\
0.2270.792±\
0.1631.428±\
0.0462.383±\
0.1460.413±\
0.09812.135±\
1.1400.893±\
0.1203 (10 mg/kg)51.998±\
0.0742.772±\
0.2810.0684±\
0.01473.819±\
0.1840.691±\
0.1411.263±\
0.1072.582±\
0.4840.352±\
0.05610.674±\
1.3631.026±\
0.0934 (20 mg/kg)51.799[a](#tbl6fna){ref-type="table-fn"}±\
0.1442.806±\
0.5650.0608±\
0.02083.679±±\
0.4411.162±\
0.4061.424±\
0.1552.344±\
0.2800.334±\
0.04112.747±\
1.0841.086±\
0.182Organ weight (g) female rats in Recovery StudyGroup (Dose)NBrainKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)51.862±\
0.1031.823±\
0.0990.0855±\
0.01750.194±\
0.0301.071±\
0.2452.272±\
0.2100.300±\
0.1207.898±\
0.7330.709±\
0.1212 (5 mg/kg)51.785±\
0.1201.927±\
0.2780.2501±\
0.34110.196±\
0.0331.076±\
0.1682.424±\
0.4680.273±\
0.0558.654±\
2.1510.889±\
0.3873 (10 mg/kg)51.956±\
0.1171.876±\
0.2430.0812±\
0.01130.189±\
0.0371.033±\
0.0862.078±\
0.2920.346±\
0.1297.633±\
0.8480.832±\
0.1994 (20 mg/kg)51.848±\
0.0451.942±\
0.3260.0869±\
0.01890.193±\
0.0421.026±\
0.1612.062±\
0.2080.283±\
0.0458.258±\
1.0240.940±\
0.168[^6]Table 7Group mean organ weights relative to brain weight (%) of rats in Recovery Study (Day 57).Table 7Relative organ to brain weight (%) of male rats in Recovery StudyGroup (Dose)NKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)5135.10±\
14.393.36±\
0.48191.52±\
9.3739.73±\
8.3472.04±\
9.99136.07±\
28.3618.68±\
2.82569.89±\
67.8143.72±\
6.462 (5 mg/kg)5150.06±\
10.163.64±\
1.75194.94±\
12.3641.23±\
9.9573.90±\
4.26123.21±\
7.8221.26±\
4.83626.32±\
42.1546.07±\
5.473 (10 mg/kg)5138.98±\
15.473.43±\
0.76191.13±\
5.7334.70±\
7.3363.22±\
4.60129.25±\
23.3817.72±\
3.37535.89±\
81.2451.33±\
3.744 (20 mg/kg)5155.16±\
24.923.38±\
1.20204.57±\
19.8465.08[a](#tbl7fna){ref-type="table-fn"}±\
23.2679.71±\
12.08130.95±\
17.3818.67±\
2.50715.81[a](#tbl7fna){ref-type="table-fn"}±\
115.4760.23[a](#tbl7fna){ref-type="table-fn"}±\
7.39Relative organ to brain weight (%) of female rats in Recovery StudyGroup (Dose)NKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)598.00±\
4.234.57±\
0.7310.47±\
1.8157.52±\
12.54122.04±\
10.0116.06±\
6.07425.66±\
50.1638.24±\
7.632 (5 mg/kg)5108.92±\
22.2114.23±\
19.3110.94±\
1.3860.85±\
13.26136.73±\
31.7115.29±\
3.06491.57±\
155.3250.79±\
25.593 (10 mg/kg)595.76±\
8.654.16±\
0.629.65±\
1.7152.87±\
4.19105.95±\
9.7717.64±\
6.23391.47±\
50.5342.38±\
8.954 (20 mg/kg)5105.16±\
18.224.70±\
1.0010.43±\
2.2055.51±\
8.56111.57±\
11.1715.31±\
2.29446.85±\
55.3750.83±\
8.89[^7]Table 8Group mean organ weights relative to body weight (%) of rats in Recovery Study (Day 57).Table 8Relative organ to body weight (%) of male rats in Recovery StudyGroup (Dose)NBrainKidneysAdrenalsTestesProstateHeartLungsThymusLiverSpleen1 (0 mg/kg)50.47±\
0.020.63±\
0.060.02±\
0.000.90±\
0.070.19±\
0.030.34±\
0.040.64±\
0.160.09±\
0.012.67±\
0.210.21±\
0.032 (5 mg/kg)50.46±\
0.030.68±\
0.050.02±\
0.010.87±\
0.110.19±\
0.050.34±\
0.040.56±\
0.040.10±\
0.022.84±\
0.130.21±\
0.023 (10 mg/kg)50.50±\
0.030.69±\
0.060.02±\
0.000.95±\
0.020.17±\
0.030.32±\
0.030.64±\
0.110.09±\
0.022.66±\
0.350.26±\
0.034 (20 mg/kg)50.43±\
0.050.68±\
0.150.01±\
0.000.89±\
0.120.28±\
0.100.34±\
0.040.56±\
0.070.08±\
0.013.06±\
0.210.26[a](#tbl8fna){ref-type="table-fn"}±\
0.05Relative organ to body weight (%) of female rats in Recovery StudyGroup (Dose)NBrainKidneysAdrenalsOvariesHeartLungsThymusLiverSpleen1 (0 mg/kg)50.64±\
0.040.62±\
0.030.03±\
0.010.07±\
0.010.36±\
0.070.78±\
0.050.10±\
0.042.70±\
0.220.24±\
0.032 (5 mg/kg)50.64±\
0.050.71±\
0.190.09±\
0.130.07±\
0.010.40±\
0.120.89±\
0.260.10±\
0.033.21±\
1.270.33±\
0.203 (10 mg/kg)50.71±\
0.060.68±\
0.080.03±\
0.000.07±\
0.010.37±\
0.020.75±\
0.100.12±\
0.042.77±\
0.220.30±\
0.074 (20 mg/kg)50.64±\
0.060.67±\
0.080.03±\
0.010.07±\
0.010.35±\
0.040.72±\
0.100.10±\
0.012.85±\
0.120.32±\
0.04[^8]Table 9Group mean hematology parameters in male rats of Main Study (Day 29).Table 9Group (Dose)NWBC\
10^3^ cells/μLRBC\
10^6^ cells/μLHGB g/dLHCT\
%MCV fLMCH pgMCHC g/dLRDW\
%1 (0 mg/kg)109.93±\
4.237.16±\
0.2913.8±\
0.641.1±\
1.757.4±\
1.219.2±\
1.033.5±\
1.411.4±\
0.62 (5 mg/kg)97.60±\
2.827.70[a](#tbl9fna){ref-type="table-fn"}±\
0.3913.3±\
0.844.5[a](#tbl9fna){ref-type="table-fn"}±\
1.457.8±\
2.217.3[a](#tbl9fna){ref-type="table-fn"}±\
0.829.9[a](#tbl9fna){ref-type="table-fn"}±\
0.911.5±\
0.93 (10 mg/kg)109.20±\
4.096.86±\
0.2612.8[a](#tbl9fna){ref-type="table-fn"}±\
0.741.2±\
1.860.0[a](#tbl9fna){ref-type="table-fn"}±\
1.018.7±\
0.431.1[a](#tbl9fna){ref-type="table-fn"}±\
0.611.5±\
0.64 (20 mg/kg)89.65±\
2.966.36[a](#tbl9fna){ref-type="table-fn"}±\
0.3312.6[a](#tbl9fna){ref-type="table-fn"}±\
0.644.8[a](#tbl9fna){ref-type="table-fn"}±\
2.070.6[a](#tbl9fna){ref-type="table-fn"}±\
2.319.8±\
0.728.0[a](#tbl9fna){ref-type="table-fn"}±\
0.812.8[a](#tbl9fna){ref-type="table-fn"}±\
1.4Group (Dose)NPLT\
10^3^ cells/μLRetic\
10^3^ cells/μLNeut\
10^3^ cells/μLLymph\
10^3^ cells/μLMono\
10^3^ cells/μLEos\
10^3^ cells/μLBaso\
10^3^ cells/μLLUC\
10^3^ cells/μL1 (0 mg/kg)10741±\
195251.1±\
51.51.81±\
1.437.57±\
2.630.32±\
0.230.13±\
0.040.04±\
0.030.05±\
0.042 (5 mg/kg)9915±\
145311.9±\
53.41.41±\
1.135.73±\
1.830.32±\
0.210.08[a](#tbl9fna){ref-type="table-fn"}±\
0.030.03±\
0.020.03±\
0.013 (10 mg/kg)10916±\
78430.5[a](#tbl9fna){ref-type="table-fn"}±\
70.71.73±\
1.196.96±\
2.680.32±\
0.350.11±\
0.040.03±\
0.020.05±\
0.024 (20 mg/kg)81175[a](#tbl9fna){ref-type="table-fn"}±\
2211190.3[a](#tbl9fna){ref-type="table-fn"}±\
151.61.96±\
0.997.16±\
2.050.34±\
0.180.09±\
0.040.04±\
0.020.06±\
0.03[^9]Table 10Group mean hematology parameters in female rats of Main Study (Day 29).Table 10Group (Dose)NWBC\
10^3^ cells/μLRBC\
10^6^ cells/μLHGB g/dLHCT\
%MCV fLMCH pgMCHC g/dLRDW\
%1 (0 mg/kg)107.15±\
2.327.11±\
0.4213.5±\
0.441.2±\
2.157.9±\
1.119.0±\
1.132.9±\
1.810.4±\
0.52 (5 mg/kg)96.36±\
2.996.66±\
1.1412.1[a](#tbl10fna){ref-type="table-fn"}±\
2.039.2±\
6.059.1±\
2.018.2±\
0.530.8[a](#tbl10fna){ref-type="table-fn"}±\
0.710.5±\
1.43 (10 mg/kg)77.03±\
2.266.36±\
0.3912.6±\
0.739.1±\
2.261.5[a](#tbl10fna){ref-type="table-fn"}±\
0.719.7±\
0.532.1±\
0.510.6±\
0.24 (20 mg/kg)85.07±\
1.835.61[a](#tbl10fna){ref-type="table-fn"}±\
0.2511.2[a](#tbl10fna){ref-type="table-fn"}±\
0.538.9±\
1.869.5[a](#tbl10fna){ref-type="table-fn"}±\
2.519.9±\
0.328.7[a](#tbl10fna){ref-type="table-fn"}±\
0.712.0[a](#tbl10fna){ref-type="table-fn"}±\
1.1Group (Dose)NPLT\
10^3^ cells/μLRetic\
10^3^ cells/μLNeut\
10^3^ cells/μLLymph\
10^3^ cells/μLMono\
10^3^ cells/μLEos\
10^3^ cells/μLBaso\
10^3^ cells/μLLUC\
10^3^ cells/μL1 (0 mg/kg)10835±\
138237.0±\
43.71.15±\
0.725.54±\
1.450.25±\
0.140.12±\
0.040.03±\
0.020.05±\
0.042 (5 mg/kg)9985±\
143294.0±\
72.81.21±\
1.224.74±\
1.820.22±\
0.110.13±\
0.040.02±\
0.010.05±\
0.033 (10 mg/kg)7912±\
100397.5[a](#tbl10fna){ref-type="table-fn"}±\
65.60.86±\
0.375.80±\
1.960.17±\
0.060.13±\
0.070.02±\
0.010.05±\
0.034 (20 mg/kg)81154[a](#tbl10fna){ref-type="table-fn"}±\
1361034.5[a](#tbl10fna){ref-type="table-fn"}±\
220.10.89±\
0.403.89±\
1.540.16±\
0.090.08±\
0.040.01[a](#tbl10fna){ref-type="table-fn"}±\
0.000.03±\
0.02[^10]Table 11Group mean hematology parameters in male rats of Recovery Study (Day 57).Table 11Group (Dose)NWBC\
10^3^ cells/μLRBC\
10^6^ cells/μLHGB g/dLHCT\
%MCV fLMCH pgMCHC g/dLRDW\
%1 (0 mg/kg)47.03±\
2.938.87±\
0.4213.9±\
0.848.5±\
2.554.6±\
0.915.7±\
0.228.7±\
0.311.5±\
0.32 (5 mg/kg)58.65±\
5.529.00±\
0.4714.5±\
0.550.0±\
2.455.5±\
1.016.1±\
0.529.0±\
0.810.4±\
0.43 (10 mg/kg)58.36±\
2.868.53±\
0.2214.3±\
0.548.3±\
1.856.5±\
1.416.7±\
0.629.5±\
0.610.1[a](#tbl11fna){ref-type="table-fn"}±\
0.84 (20 mg/kg)56.69±\
2.658.54±\
0.5514.9±\
1.149.3±\
3.857.8[a](#tbl11fna){ref-type="table-fn"}±\
1.517.5[a](#tbl11fna){ref-type="table-fn"}±\
1.030.2[a](#tbl11fna){ref-type="table-fn"}±\
1.410.2[a](#tbl11fna){ref-type="table-fn"}±\
0.8Group (Dose)NPLT\
10^3^ cells/μLRetic\
10^3^ cells/μLNeut\
10^3^ cells/μLLymph\
10^3^ cells/μLMono\
10^3^ cells/μLEos\
10^3^ cells/μLBaso\
10^3^ cells/μLLUC\
10^3^ cells/μL1 (0 mg/kg)41032±\
141208.3±\
34.41.21±\
0.505.52±\
2.570.16±\
0.070.09±\
0.030.03±\
0.020.03±\
0.012 (5 mg/kg)51015±\
160210.4±\
29.52.11±\
2.246.09±\
3.340.26±\
0.210.09±\
0.030.04±\
0.030.06±\
0.053 (10 mg/kg)51047±\
151234.3±\
51.72.07±\
1.425.86±\
1.340.26±\
0.150.11±\
0.060.03±\
0.020.04±\
0.024 (20 mg/kg)5795±\
119205.2±\
36.01.15±\
0.585.24±\
2.030.16±\
0.080.09±\
0.030.03±\
0.020.03±\
0.02[^11]Table 12Group mean hematology parameters in female rats of Recovery Study (Day 57).Table 12Group (Dose)NWBC\
10^3^ cells/μLRBC\
10^6^ cells/μLHGB g/dLHCT\
%MCV fLMCH pgMCHC g/dLRDW\
%1 (0 mg/kg)54.82±\
1.568.58±\
0.3814.4±\
0.448.6±\
1.256.7±\
1.816.8±\
0.429.6±\
0.210.0±\
0.22 (5 mg/kg)47.54±\
1.868.28±\
0.6614.4±\
0.747.1±\
2.456.9±\
1.717.5±\
0.830.7±\
0.89.4±\
0.23 (10 mg/kg)45.37±\
0.888.03±\
0.6214.1±\
0.746.5±\
3.557.9±\
0.617.6±\
0.530.4±\
0.78.9±\
0.44 (20 mg/kg)56.20±\
2.167.30±\
1.5013.4±\
1.944.8±\
6.062.4±\
6.318.7±\
2.230.0±\
1.310.7±\
2.7Group (Dose)NPLT\
10^3^ cells/μLRetic\
10^3^ cells/μLNeut\
10^3^ cells/μLLymph\
10^3^ cells/μLMono\
10^3^ cells/μLEos\
10^3^ cells/μLBaso\
10^3^ cells/μLLUC\
10^3^ cells/μL1 (0 mg/kg)5994±\
133206.1±\
32.30.82±\
0.443.72±\
1.110.12±\
0.050.11±\
0.060.02±\
0.010.02±\
0.012 (5 mg/kg)4911±\
172186.0±\
13.21.43±\
0.475.65±\
1.380.24±\
0.100.16±\
0.080.03±\
0.010.04±\
0.023 (10 mg/kg)4998±\
220171.1±\
68.40.92±\
0.324.19±\
0.940.14±\
0.050.07±\
0.030.02±\
0.010.03±\
0.014 (20 mg/kg)5948±\
227307.1±\
296.21.45±\
1.324.30±\
1.330.20±\
0.090.19±\
0.100.02±\
0.010.04±\
0.03[^12]Table 13Group mean clinical chemistry parameters in male rats of Main Study (Day 29).Table 13Group (Dose)NGlob g/dLAlb g/dLA/G ratioAST\
U/LALP\
U/LALT\
U/LCa mg/dLChol mg/dLCreat mg/dLGGT\
U/L1 (0 mg/kg)102.35±\
0.213.09±\
0.171.32±\
0.13152.2±\
26.8136.2±\
21.960.6±\
8.89.72±\
0.2893.8±\
10.70.62±\
0.06\<4.02 (5 mg/kg)92.27±\
0.203.06±\
0.191.36±\
0.15143.9±\
35.6132.3±\
40.256.0±\
10.99.60±\
0.3189.0±\
5.70.59±\
0.04\<4.03 (10 mg/kg)102.55±\
0.183.27[a](#tbl13fna){ref-type="table-fn"}±\
0.161.29±\
0.13157.9±\
21.1166.9±\
24.973.8[a](#tbl13fna){ref-type="table-fn"}±\
11.39.85±\
0.23100.1±\
8.10.62±\
0.05\<4.04 (20 mg/kg)82.48±\
0.153.24±\
0.111.31±\
0.10127.0±\
13.3143.6±\
42.061.4±\
9.810.13[a](#tbl13fna){ref-type="table-fn"}±\
0.1695.2±\
7.60.60±\
0.02\<4.0Group (Dose)NGluc mg/dLPhos mg/dLTBil mg/dLTrig mg/dLBUN mg/dLTPro g/dLNa mmol/LK mmol/LCl mmol/LCK\
U/L1 (0 mg/kg)10180.18±\
60.707.85±\
0.420.06±\
0.0323.93±\
7.1018.66±\
2.975.45±\
0.28138.7±\
1.45.37±\
0.5296.8±\
0.81342.1±\
467.62 (5 mg/kg)9200.86±\
40.379.18[a](#tbl13fna){ref-type="table-fn"}±\
0.880.05±\
0.0528.52±\
11.1419.22±\
3.215.33±\
0.24144.1±\
16.56.10±\
1.89101.5±\
15.21083.6±\
365.43 (10 mg/kg)10120.16[a](#tbl13fna){ref-type="table-fn"}±\
39.238.21±\
0.830.16[a](#tbl13fna){ref-type="table-fn"}±\
0.0239.52±\
17.1517.95±\
3.495.82[a](#tbl13fna){ref-type="table-fn"}±\
0.18141.3±\
1.95.14±\
0.2896.7±\
1.01260.5±\
330.44 (20 mg/kg)8112.09[a](#tbl13fna){ref-type="table-fn"}±\
32.138.48±\
0.480.17[a](#tbl13fna){ref-type="table-fn"}±\
0.0752.72[a](#tbl13fna){ref-type="table-fn"}±\
20.1516.42±\
2.475.73[a](#tbl13fna){ref-type="table-fn"}±\
0.16140.3±\
1.25.35±\
0.3196.3±\
1.5851.8[a](#tbl13fna){ref-type="table-fn"}±\
285.9[^13]Table 14Group mean clinical chemistry parameters in female rats of Main Study (Day 29).Table 14Group (Dose)NGlob g/dLAlb g/dLA/G ratioAST\
U/LALP\
U/LALT\
U/LCa mg/dLChol mg/dLCreat mg/dLGGT\
U/L1 (0 mg/kg)102.41±\
0.263.26±\
0.151.36±\
0.15138.0±\
34.087.1±\
14.647.4±\
6.99.99±\
0.25103.5±\
8.20.69±\
0.04\<4.02 (5 mg/kg)92.39±\
0.183.11±\
0.201.31±\
0.11126.2±\
26.6126.5[a](#tbl14fna){ref-type="table-fn"}±\
42.345.1±\
7.49.95±\
0.24106.0±\
9.70.65±\
0.04\<4.03 (10 mg/kg)72.46±\
0.123.38±\
0.101.37±\
0.07147.5±\
18.0107.3±\
25.658.8[a](#tbl14fna){ref-type="table-fn"}±\
6.610.11±\
0.23128.2[a](#tbl14fna){ref-type="table-fn"}±\
18.90.64[a](#tbl14fna){ref-type="table-fn"}±\
0.02\<4.04 (20 mg/kg)82.21±\
0.183.23±\
0.151.46±\
0.08104.7[a](#tbl14fna){ref-type="table-fn"}±\
9.2102.6±\
24.544.7±\
10.99.94±\
0.29113.0±\
11.50.63[a](#tbl14fna){ref-type="table-fn"}±\
0.05\<4.0Group (Dose)NGluc mg/dLPhos mg/dLTBil mg/dLTrig mg/dLBUN mg/dLTPro g/dLNa mmol/LK mmol/LCl mmol/LCK\
U/L1 (0 mg/kg)10132.15±\
19.948.12±\
1.300.06±\
0.0537.18±\
20.0219.70±\
3.225.68±\
0.28138.4±\
1.95.66±\
1.4897.6±\
1.51087.7±\
437.82 (5 mg/kg)9159.58±\
28.118.53±\
1.080.10±\
0.0646.52±\
25.3722.44±\
1.575.50±\
0.30137.8±\
1.05.71±\
1.1897.4±\
1.2481.5[a](#tbl14fna){ref-type="table-fn"}±\
223.83 (10 mg/kg)7120.18±\
29.187.82±\
0.760.13±\
0.1253.24±\
35.8217.03±\
2.785.84±\
0.17139.9±\
1.75.26±\
0.7298.0±\
1.51063.7±\
169.84 (20 mg/kg)8161.45±\
26.897.45±\
0.780.19[a](#tbl14fna){ref-type="table-fn"}±\
0.0539.50±\
14.7518.24±\
4.665.44±\
0.30138.2±\
1.55.04±\
0.3297.6±\
2.4638.7[a](#tbl14fna){ref-type="table-fn"}±\
303.0[^14]Table 15Group mean clinical chemistry parameters in male rats of Recovery Study (Day 57).Table 15Group (Dose)NGlob g/dLAlb g/dLA/G ratioAST\
U/LALP\
U/LALT\
U/LCa mg/dLChol mg/dLCreat mg/dLGGT\
U/L1 (0 mg/kg)52.50±\
0.203.07±\
0.191.24±\
0.14171.9±\
71.693.5±\
13.458.0±\
4.59.56±\
0.3399.7±\
11.10.63±\
0.02\<4.02 (5 mg/kg)52.46±\
0.303.12±\
0.241.28±\
0.11120.0±\
19.381.5±\
17.154.4±\
7.59.46±\
0.8794.2±\
8.00.63±\
0.06\<4.03 (10 mg/kg)52.54±\
0.183.05±\
0.141.20±\
0.10149.0±\
18.984.7±\
22.238.9[a](#tbl15fna){ref-type="table-fn"}±\
3.69.40±\
0.35100.6±\
4.40.57±\
0.01\<4.04 (20 mg/kg)52.60±\
0.153.06±\
0.131.18±\
0.03109.0±\
23.685.4±\
9.944.1[a](#tbl15fna){ref-type="table-fn"}±\
7.49.67±\
0.2485.8±\
15.00.57±\
0.05\<4.0Group (Dose)NGluc mg/dLPhos mg/dLTBil mg/dLTrig mg/dLBUN mg/dLTPro g/dLNa mmol/LK mmol/LCl mmol/LCK\
U/L1 (0 mg/kg)5125.59±\
18.377.34±\
0.520.07±\
0.0525.79±\
6.5017.81±\
2.885.57±\
0.24139.7±\
2.05.58±\
0.3697.4±\
0.81297.5±\
441.82 (5 mg/kg)5134.91±\
25.468.47±\
1.040.07±\
0.0520.03±\
3.8619.25±\
2.295.59±\
0.50138.4±\
1.77.24±\
3.8496.9±\
1.6881.8±\
328.13 (10 mg/kg)5105.16±\
43.478.24±\
0.480.12±\
0.0322.28±\
9.5017.29±\
2.525.59±\
0.25139.3±\
1.26.51±\
1.5697.5±\
1.01303.2±\
122.64 (20 mg/kg)5146.98±\
40.717.92±\
0.810.06±\
0.0124.81±\
10.3717.49±\
0.945.67±\
0.27140.9±\
2.25.63±\
0.1697.6±\
2.3740.0[a](#tbl15fna){ref-type="table-fn"}±\
336.1[^15]Table 16Group mean clinical chemistry parameters in female rats of Recovery Study (Day 57).Table 16Group (Dose)NGlob g/dLAlb g/dLA/G ratioAST\
U/LALP\
U/LALT\
U/LCa mg/dLChol mg/dLCreat mg/dLGGT\
U/L1 (0 mg/kg)52.46±\
0.283.31±\
0.091.36±\
0.16162.1±\
29.259.6±\
10.144.8±\
7.89.76±\
0.19103.7±\
7.40.65±\
0.04\<4.02 (5 mg/kg)42.38±\
0.353.15±\
0.171.34±\
0.17165.8±\
30.6101.1±\
69.040.1±\
5.09.52±\
0.2588.8±\
9.70.69±\
0.06\<4.03 (10 mg/kg)52.81±\
0.243.12±\
0.151.12±\
0.12137.3±\
12.7122.4±\
115.039.1±\
4.49.78±\
0.20107.6±\
15.10.67±\
0.07\<4.04 (20 mg/kg)42.63±\
0.283.04[a](#tbl16fna){ref-type="table-fn"}±\
0.091.17±\
0.13114.6[a](#tbl16fna){ref-type="table-fn"}±\
12.390.4±\
33.134.3[a](#tbl16fna){ref-type="table-fn"}±\
2.29.64±\
0.42112.1±\
23.50.58±\
0.03\<4.0Group (Dose)NGluc mg/dLPhos mg/dLTBil mg/dLTrig mg/dLBUN mg/dLTPro g/dLNa mmol/LK mmol/LCl mmol/LCK\
U/L1 (0 mg/kg)5111.28±\
25.477.93±\
0.980.11±\
0.0330.22±\
4.8020.28±\
2.905.77±\
0.26139.1±\
1.25.77±\
1.1897.9±\
1.91231.1±\
367.62 (5 mg/kg)4100.18±\
15.117.66±\
0.380.11±\
0.0528.04±\
6.5020.52±\
2.005.54±\
0.50140.5±\
2.35.14±\
0.7498.9±\
1.01402.3±\
454.93 (10 mg/kg)595.88±\
17.327.48±\
1.380.11±\
0.0527.80±\
5.8120.97±\
2.605.93±\
0.21141.7±\
2.45.36±\
0.1399.7±\
1.81141.8±\
342.44 (20 mg/kg)4117.28±\
13.427.17±\
0.810.09±\
0.0325.92±\
12.9020.17±\
4.975.67±\
0.27141.0±\
1.84.84±\
0.7698.9±\
0.6760.2[a](#tbl16fna){ref-type="table-fn"}±\
376.4[^16]

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Animals {#sec2.1}
------------

Male and female Sprague-Dawley rats with femoral vein catheters (FVC) (Envigo, Surgical Facility 237, Livermore, CA) were used. The studies were conducted in AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) accredited BTS Research (San Diego, CA), the contract research organization (CRO). Animals were acclimated to the laboratory environment for a period of 7--8 days. Animals were individually housed in polycarbonate cages containing animal bedding and provided Certified Teklad Rodent Chow 2918 C feed and water at *ad libitum*. The animals were maintained in environmentally controlled room conditions (18--23 °C, 30--70% relative humidity). At the initiation of dosing, rats were 7--9 weeks old with body weights ranging from 180 to 260 g for males and 160--240 g for females. The in-life procedures were performed at BTS Research in accordance with "U.S. Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations; Final Rule. 21 CFR Part 58, October 5, 1987" and BTS Standard Operating Procedures (SOPs).

2.2. Dose formulation {#sec2.2}
---------------------

Sepin-1 was synthesized by ChemBridge (San Diego, CA). A 40 mg/ml stock solution was prepared by dissolving Sepin-1 in DMSO. Dosing solution for the group receiving 20 mg/kg was prepared by diluting 40 mg/ml stock to 4 mg/ml in 0.01 M citrate-buffed saline (CBS) (0.8%), pH 4.0. The subsequent dosing solutions of 1 and 2 mg/ml were prepared by diluting 4 mg/ml in vehicle control buffer consisting of CBS with 10% dimethyl sulfoxide (CBSD). Dose formulations were prepared daily, and formulations from days 1 and 28 were assessed for drug concentration, homogeneity, and stability by Keystone Bioanalytical (North Wales, PA) using a validated method. All dose solutions were within ±10% of intended concentrations.

2.3. Dosing and Catheter Maintenance {#sec2.3}
------------------------------------

The patency of the FVC was restored every time for dosing. First, exteriorized septum port of FVC was wiped with alcohol wipe or gauze sprayed with 70% alcohol. Then, an appropriate sterile adapter was attached to a 1 ml syringe to access the septum port and withdraw the lock solution until blood is observed. Next, a preloaded syringe was attached, and the preloaded formulated test article was injected at a rate of approximately 2 ml/min. In addition, a preloaded third syringe was attached to inject sterile saline to the flush the line via the adapter (up to 0.4 ml). Finally, a preloaded fourth syringe was attached to inject required amount of lock solution as determined by surgical vendor documentation for FVC indwelling dead volume.

2.4. Experimental design {#sec2.4}
------------------------

### 2.4.1. Toxicity Study {#sec2.4.1}

A total of 120 Sprague-Dawley rats with indwelling FVCs were randomly assigned to four dose groups (0, 5, 10, or 20 mg/kg/day corresponding to Group 1, 2, 3 and 4, respectively) in the Main Study (40 males and 40 females) and Recovery Study (20 males and 20 females). The animals were dosed via bolus intravenous injection once daily for 28 consecutive days. Animals assigned to the Main Study were euthanized on Day 29 and subjected to histopathological evaluations. The animals in the Recovery Study remained on study for a 28-day off-dose observation period followed by euthanasia and necropsy on Day 29 of the recovery period for histopathological evaluations. Toxicological parameters evaluated were mortality, clinical observations, body weights, food consumption, ophthalmoscopy, clinical pathology (hematology, coagulation, clinical chemistry, and urinalysis), necropsy, organ weights, and histopathology. Unscheduled dead animals were also subjected to necropsy evaluations.

### 2.4.2. In-life Observations {#sec2.4.2}

All animals were observed daily for clinical signs; detailed clinical observations were done once daily during dosing days and once weekly during recovery and prior to necropsy at 4 hours. Individual food consumption was recorded weekly; individual body weights were recorded once during acclimation and at least twice per week during dosing and recovery periods. Ophthalmic evaluations (Direct and Slit-Lamp) of animals in both the Main and Recovery Studies were conducted prior to initiation of treatment and towards the end of the 4th week of the dosing period.

### 2.4.3. Clinical Pathology {#sec2.4.3}

Animals were fasted for at least 8 hours prior to collection of blood for clinical pathology (hematology and clinical chemistry) evaluations at scheduled necropsy on Day 29 (Main Study) and 57 (Recovery Study). Clotted blood samples were centrifuged, and the serum was used for the following clinical chemistry analyses using Randox Imola Clinical Chemistry Analyzer (Randox Laboratories-US, Ltd, Kearneysville, WV): alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, phosphorus, potassium, and sodium. Blood samples collected with K~2~EDTA were analyzed for the following hematology parameters using Siemens Advia 120 Hematology System (Siemens Healthineers, Erlangen, Germany): hemoglobin, hematocrit, platelet counts, leukocyte cell types, and red cell indices (MCV, MCH, and MCHC).

### 2.4.4. Body and organ weight {#sec2.4.4}

Individual body weights were collected from all animals once during acclimation, and at least twice per week for dosing and recovery phase animals. Body weights were collected prior to the withdrawal of food for overnight fasting when fasting and body weights fell on the same day.

At the end of study, animals were euthanized via inhalation of isoflurane at 5% followed by exsanguination. Complete necropsy examinations were done for all animals. The organs weighted were brain, adrenal gland, prostate gland, heart, kidney, liver, lung, ovary, spleen, testis, and thymus. Organ weight as a percent of body weight (using the terminal body weight) and organ weight as a percent of brain weight were calculated.

2.5. Statistical evaluation {#sec2.5}
---------------------------

Data for male and female rats were analyzed separately. All statistics were calculated in Minitab version 16.2.4 by performing an Equal Variance Test with a confidence interval of 95% followed by a One-Way ANOVA with a confidence interval of 95% and a Dunnett comparison test with a family error rate of 5%. Any data that were found to be statistically significant by the Levene\'s Test P-Value in the Equal Variance Test were normalized by taking the square root of the data and adapting the confidence interval and family error rate for the One-Way ANOVA and Dunnett\'s comparison test, respectively.
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